Ivonescimab Clinical Trials

25 actively recruiting trials across 7 locations

Also known as: AK 112, AK-112, AK112, AK112/SMT112, Adapted Guided Stereotactic Body Radiotherapy +7 more

Pipeline

Phase 2: 20Phase 1/2: 5

Top Sponsors

M.D. Anderson Cancer Center3
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology2
UNICANCER2
Fudan University2
University of Michigan Rogel Cancer Center1

Indications

Cancer25
Lung Cancer6
Breast Cancer3
Pancreatic Cancer2
Advanced Solid Tumors2

Other15 trials

A Study of Ivonescimab in First-Line ES-SCLC

Phase 2

A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors

Phase 1/2

AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer

Phase 2

Adapted Guided Stereotactic Body Radiotherapy Combined with Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND)

Phase 1/2

Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial

Phase 2

Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy

Phase 2

First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors

Phase 1/2

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Phase 2

Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer

Phase 2

Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC

Phase 2

Short-course Radiotherapy Followed by AK112 and CAPOX as Neoadjuvant Therapy for Locally Advanced Rectal Cancer

Phase 2

Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients

Phase 2

Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma

Phase 2

ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)

Phase 2

ctDNA-guided Treatment Decision-making

Phase 2

Houston, Texas3 trials

A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma

The University of Texas M. D. Anderson Cancer Center

Phase 1/2

Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer

The University of Texas M. D. Anderson Cancer Center

Phase 2

Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma

MD Anderson Cancer Center

Phase 2

Los Angeles, California2 trials

Ivonescimab for the Treatment of Thymic Cancer

UCLA / Jonsson Comprehensive Cancer Center

Phase 2

Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer

Cedars-Sinai Medical Center

Phase 2

Santa Monica, California1 trial

Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA

UCLA

Phase 2

Boston, Massachusetts1 trial

A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers

Brigham and Women's Hospital

Phase 2

Ann Arbor, Michigan1 trial

Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer

University of Michigan Comprehensive Cancer Center

Phase 2

Basking Ridge, New Jersey1 trial

A Study of Ivonescimab in People With Endometrial and Cervical Cancers

Memorial Sloan Kettering Basking Ridge (All Protocol Activities)

Phase 2

Fairfax, Virginia1 trial

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

NEXT Virginia

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.